Current perspectives on bioresorbable scaffolds in coronary intervention and other fields

Xinlei Wu,Sijing Wu,Hideyuki Kawashima,Hironori Hara,Masafumi Ono,Chao Gao,Rutao Wang,Mattia Lunardi,Faisal Sharif,William Wijns,Patrick W. Serruys,Yoshinobu Onuma
DOI: https://doi.org/10.1080/17434440.2021.1904894
IF: 3.439
2021-03-30
Expert Review of Medical Devices
Abstract:<span><b>Introduction</b>: The first-generation bioresorbable scaffolds (BRSs) had a large strut profile to compensate for the insufficient radial strength of bioresorbable polymer materials, resulting in higher scaffold thrombosis rates than conventional drug-eluting stents. To improve the clinical safety and efficacy, the new generation BRSs have been improved by optimal structure design, post-processing of bioresorbable polymer materials, or altering bioresorbable metallic alloys.<b>Areas covered</b>: This review summarizes the lessons learned from the first-generation BRS, updates the clinical outcomes of trials evaluating ABSORB bioresorbable vascular scaffold at long-term and bioresorbable metallic alloy-based devices, and examines recent outcomes of BRS treated in STEMI patients. This review also provides an overview of the current clinical data of seven BRSs manufactured in Asia, and of the BRSs extended application in other clinical arenas.<b>Expert opinion</b>: Drawbacks of the first-generation BRSs need to be addressed by the next generation of these stents with novel materials and technologies. Clinical research, including randomized controlled trials, are required to further evaluate BRSs application in coronary artery disease. The encouraging results of BRSs innovation applied in the peripheral arteries and gastrointestinal tracts support other potential clinical applications of BRS technology.</span>
engineering, biomedical
What problem does this paper attempt to address?